ABVC BioPharma Experiences Surge in Short Interest

In January, ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant increase in short interest, indicating a rise in the number of investors betting against the company's stock performance. The short interest on January 15th reached 132,400 shares, marking an impressive 717.3% escalation from the count of 16,200 shares on December 31st. This surge suggests that 1.9% of ABVC BioPharma's shares are now held short.

ABVC BioPharma's Market Movement

The stock of ABVC BioPharma started trading at $1.30 on a recent Friday, with past movements indicating fluctuations in the market. The company has seen its share value hit a 12-month low of $0.67 and peak at a 12-month high of $9.60. The 50-day and 200-day simple moving averages stand at $1.37 and $1.63, respectively, offering insights into its short-term and long-term performance trends.

Financial Highlights

Financial reports from November 15th showed that ABVC BioPharma reported a quarterly earnings per share (EPS) of ($0.82). The revenue was a modest $0.02 million. However, the company's financial health seems strained with a negative net margin of 1,611.23% and a negative return on equity amounting to 348.52%, indicating considerable losses in relation to equity.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biopharmaceutical venture, focusing on the development of drugs and medical devices for unserved medical needs in the U.S. Its portfolio includes a diverse range of drugs in different stages of clinical trials, targeting conditions such as triple negative breast cancer, major depressive disorders, adult attention deficit hyperactivity disorder, metastatic pancreatic cancer, myelodysplastic syndromes, and non-small cell lung cancer.

ShortInterest, BioPharma, StockPerformance